Comments
Biopharmaceutical company Biocon Ltd's shares fell as much as 3 per cent to Rs 607.05 in early trade on Thursday, their biggest intra-day per cent loss since February 15.
The company’s Bengaluru-based insulin drug substance manufacturing facility has got six Form 483 observations from the US FDA, Biocon said on Wednesday.
The FDA Form 483 notifies a company's management of objectionable conditions. More than 1.5 million shares changed hands, compared with the 30-day average volume of around 1.4 million shares.
The stock has hit its lowest level since February 19. The stock was down 0.47 per cent this year, as of last close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.